109 results on '"Heidenreich, Axel"'
Search Results
2. Interim analysis of the prospective COTRIMS (Cologne Trial of Retroperitoneal Lymphadectomy in Metastatic Seminoma) trial.
3. Prediction of response to neoadjuvant chemotherapy of patients with muscle invasive bladder cancer by molecular subtyping and radioligand target quantitation: Preview of the Bladder BRIDGister.
4. Evaluation of miRNA-371a-3p (miR371a) assay to predict final pathohistology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy (nsRPLND) for stage IIA/B seminomas and non-seminomas.
5. Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.
6. Validation of AGR2 and KRT19 as specific proteins being significantly and differentially expressed in teratoma compared to necrosis in retroperitoneal lymph node resections after chemotherapy (pcRPLND).
7. Prediction of response to neoadjuvant chemotherapy of patients with muscle invasive bladder cancer by molecular subtyping and antibody drug conjugate target gene quantitation: Preview of Bladder BRIDGister.
8. Relapse-free and overall survival in patients with non-seminomatous testicular germ cell tumours with teratoma-free primaries.
9. Cytoreductive radical prostatectomy (cRP) in the management of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
10. Need for organ preservation in postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).
11. Identifying patient profiles and mapping the patient journey across three countries in a large-scale, fully digital survey of patients with prostate cancer.
12. Association of nonseminomatous testicular germ cell tumors with teratoma-free primaries with disease relapse and overall survival.
13. Nerve sparing retroperitoneal lymph node dissection in clinical stage IIA/B seminoma: The COTRIMS trial.
14. PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).
15. Viable germ cell tumor and teratoma can be distinguished from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens by a combination of microRNA-371a-3p and 375-5p.
16. Progression-free survival, PFS, depending on the site of lymph-node metastases in patients after salvage lymph node dissection, sLAD, in lymph node only recurrent prostate cancer.
17. Differentially expressed mRNA/proteins can distinguish viable germ cell tumors and teratomas from necrosis in retroperitoneal lymph node resections after chemotherapy (pcRPLND).
18. 68 Ga-PSMA PET/CT for preoperative lymph nosde staging of high-risk prostate cancer.
19. Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
20. Impact of human papillomavirus (HPV) infection on the outcome of perioperative treatments for penile squamous-cell carcinoma (PSCC).
21. Late toxicities and recurrences in patients with clinical stage I nonseminomatous germ cell tumor after one cycle of adjuvant BEP versus primary retroperitoneal lymph node dissection: A 13-years follow-up analysis of a phase III trial cohort.
22. Treatment patterns and outcomes of patients with penile squamous-cell carcinoma (PSCC) undergoing inguinal lymph node dissection (ILND): An analysis of a multicenter contemporary database.
23. Feasibility and oncologic outcome of salvage surgery in isolated seminal vesical remnants after radical prostatectomy.
24. PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).
25. Validation and implementation of a mobile app decision support system for quality assurance of tumor boards: Analyzing the concordance rates for testis cancer at a multidisciplinary tumor board of a tertiary referral center.
26. Prognostic impact of LDH and HCG levels in marker-positive seminomas.
27. Development of a risk calculator of recurrence in inguinal lymph node metastatic (ILNM) patients with surgically resected penile squamous cell carcinoma (PSCC).
28. Evaluation of the oncologic benefit of adjunctive surgery at time of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).
29. Validation of the two best models to predict “benign” pathohistology in patients with advanced nonseminomatous germ cell tumors (NSGCT) undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).
30. Exenterative surgery to improve quality of life on men with locally advanced, symptomatic castration-resistant prostate cancer.
31. Regression tree analysis to identify the best candidates for neoadjuvant chemotherapy (NAC) in patients with clinically lymph node-positive penile squamous cell carcinoma (PSCC).
32. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
33. PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).
34. Analysis of three models to predict pathohistology in patients undergoing postchemotherapy RPLND for (pcRPLND) advanced nonseminomatous germ cell tumors (NSGCT).
35. Predicting vital retroperitoneal residual tumors of metastatic testicular tumor patients after chemotherapy using radiomics.
36. Predicting overall survival (OS) in patients (pts) with penile squamous cell carcinoma (PSCC) undergoing regional lymph node dissection (LND) ± multimodal therapy.
37. Seminomatous germ cell tumors are heterogenic and metastasis can be predicted based on a gene signature of the tumor invasive front.
38. Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma.
39. Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.
40. Comprehensive analysis of metastatic seminoma germ cell tumors shows divergent expression of immune-related pathways.
41. Biochemichal recurrence in prostate cancer after salvage surgery in correlation to the site of reccurrent disease.
42. Next Generation Sequencing (NGS) in metastatic castration resistant prostate cancer (mCRPC) to identify targets for individualized treatment: Is it feasible in daily routine?
43. Identification of differentially expressed genes to predict radioresistant prostate carcinomas.
44. Vimentin 3 and endothelin in prostate cancer.
45. Hepatic effects assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.
46. Functional outcome and quality of life in patients undergoing salvage radical prostatectomy (SRPE).
47. The role of reference pathology to assess MRI-TRUS fusion prostate biopsies in a tertiary referral center.
48. 68-Ga-PSMA-PET in the diagnosis of local recurrent disease after radiotherapy in patients with prostate cancer.
49. Management of growing teratoma syndrome (GTS): Results of the German Testicular Cancer Study Group.
50. 68-Ga-PSMA-PET in lymph node staging in PSA recurrent prostate cancer-does the primary influence the result?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.